Inventiva S.A./€IVA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Inventiva S.A.
Inventiva S.A. is a clinical-stage biopharmaceutical company based in France, focused on developing oral small molecule therapies for the treatment of diseases with unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company’s leading product candidate is lanifibranor, which is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2012, Inventiva leverages its proprietary technology platform to identify and develop innovative compounds. The company's research and development operations are concentrated in Daix, France. Inventiva’s competitive strength lies in its robust pipeline and strategic collaborations with partners in the pharmaceutical industry. Sources:
1. https://inventivapharma.com/en/
2. https://ir.inventivapharma.com/
3. https://www.wallstreet-online.de/nachricht/14672309-inventiva-reports-financial-results-quarter-ended-september-30-2021
- Ticker
- €IVA
- Sector
- Health
- Primary listing
- PAR
- Employees
- 87
- Headquarters
- Daix, France
- Website
- inventivapharma.com
Inventiva S.A. Metrics
BasicAdvanced
€803M
-
-€0.92
1.00
-
Price and volume
Market cap
€803M
Beta
1
52-week high
€6.16
52-week low
€2.70
Average daily volume
693K
Financial strength
Current ratio
3.808
Quick ratio
2.733
Long term debt to equity
2.127
Total debt to equity
2.352
Interest coverage (TTM)
-3.83%
Profitability
EBITDA (TTM)
-149.059
Gross margin (TTM)
78.26%
Net profit margin (TTM)
-10,086.44%
Operating margin (TTM)
-5,980.94%
Effective tax rate (TTM)
-0.25%
Revenue per employee (TTM)
€30,000
Management effectiveness
Return on assets (TTM)
-40.56%
Return on equity (TTM)
-989.05%
Valuation
Price to revenue (TTM)
370.726
Price to book
13.62
Price to tangible book (TTM)
13.69
Price to free cash flow (TTM)
-9.391
Free cash flow yield (TTM)
-10.65%
Free cash flow per share (TTM)
-0.36
Growth
Revenue change (TTM)
-85.53%
Earnings per share change (TTM)
-73.90%
3-year revenue growth (CAGR)
-51.88%
10-year revenue growth (CAGR)
-14.48%
3-year earnings per share growth (CAGR)
-21.53%
10-year earnings per share growth (CAGR)
0.99%
What the Analysts think about Inventiva S.A.
Analyst ratings (Buy, Hold, Sell) for Inventiva S.A. stock.
Analyst projections of the future price of Inventiva S.A. stock.
Bulls say / Bears say
NATiV3 has completed its 72-week treatment period in 1,009 main-cohort patients, with topline data expected in Q4 2026. A positive result could support a regulatory filing in the first half of 2027. (GlobeNewswire)
The earlier Phase IIb trial produced encouraging signals: a placebo-adjusted 18% improvement in fibrosis and 26% MASH resolution after six months. NATiV3 is testing the treatment in a much larger pivotal study, giving investors a potential route to confirm that activity. (The Motley Fool)
Recent equity and debt financing left Inventiva with €233.9 million in cash and short-term deposits at June 2026, and management expects funding through Q2 2027. That is intended to cover the Phase III readout and a potential regulatory filing. (GlobeNewswire)
The investment case remains highly dependent on one unproven medicine: NATiV3 results are still pending, and lanifibranor remains investigational, with its safety and efficacy not established by regulators. A disappointing Phase III result could sharply weaken the company’s prospects. (SEC)
The company’s stated runway reaches only the end of Q2 2027 under current funding assumptions, and it says its current resources alone do not cover the next 12 months. Extending runway into 2028 depends on further debt financing and warrant exercises, which are not assured. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
Inventiva S.A. Financial Performance
Revenues and expenses
Inventiva S.A. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Inventiva S.A.
Fund name | Fund size | €IVA weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.02% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.02% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.